(Pharmamar) PharmaMar has announced today that the Independent Data Monitoring Committee has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre® (lurbinectedin, PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without any changes.
